Morgan Stanley Lowers Personalis (PSNL) Price Target to $10

Personalis, Inc. (NASDAQ:PSNL) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts.

Morgan Stanley Lowers Personalis (PSNL) Price Target to $10

On March 5, 2026, Personalis, Inc. (NASDAQ:PSNL) saw its price target from Morgan Stanley lowered from $11 to $10. The firm’s analyst maintained an Equal Weight rating on the stock after updating its estimates to reflect an increased 2026 net loss guidance and higher projected long-term operating expenses.

In another development, on March 12, 2026, Personalis, Inc. (NASDAQ:PSNL) announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology. The study highlighted the effectiveness of its NeXT Personal assay in monitoring breast cancer. It tracks up to 1,800 tumor-specific variants to provide precise risk-stratification. Richard Chen, MD, Chief Medical Officer and Executive Vice President, R&D, Personalis, Inc. (NASDAQ:PSNL), gave the following statement:

The results of this study suggest that an ultrasensitive ctDNA assay like NeXT Personal could help patients better understand their response to neoadjuvant therapy, with the potential to help inform the need for additional therapy.

Founded in 2011, Personalis, Inc. (NASDAQ:PSNL) is a cancer genomics leader specializing in ultrasensitive liquid biopsy tests for minimal residual disease (MRD). Its headquarters is in California.

While we acknowledge the risk and potential of PSNL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PSNL and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Stocks to Invest in During a Recession and 10 Best Space Exploration Stocks to Buy According to Analysts

Disclosure: None.  Follow Insider Monkey on Google News.